Cover Image
市場調查報告書

遲發性運動障礙:美國、日本市場分析

Tardive Dyskinesia Market Report: Focus on US & Japan 2016-2025

出版商 Koncept Analytics 商品編碼 520491
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
遲發性運動障礙:美國、日本市場分析 Tardive Dyskinesia Market Report: Focus on US & Japan 2016-2025
出版日期: 2017年06月22日 內容資訊: 英文 51 Pages
簡介

本報告提供美國及日本的遲發性運動障礙市場相關詳細分析,疾病概要和病因、治療方法,美國、日本國內的患者數、市場規模趨勢預測 (今後10年份),主要的治療藥的普及率,主要的調查推動及阻礙市場要素,主要企業的業績、產業策略等。

第1章 遲發性運動障礙:概要

  • 思覺失調症治療藥概要
  • 遲發性運動障礙
  • 症狀和前兆
  • 病因
  • 治療方法
  • 現有/開發平台醫藥品

第2章 美國的遲發性運動障礙市場分析

  • 遲發性運動障礙的患者數
  • 各重症度的患者數
  • 銷售額 (以金額為準)
  • 年度價格趨勢

第3章 日本的遲發性運動障礙市場分析

第4章 美國的遲發性運動障礙治療藥市場分析

  • 美國的Valbenazine市場:普及率
  • 美國的SD-809市場:普及率
  • 美國的Tetrabenazine市場:普及率

第5章 市場動態

  • 成長推動因素
  • 市場趨勢
  • 課題

第6章 競爭環境

  • Valbenazine和SD-809比較

第7章 企業簡介

目錄

Tardive dyskinesia is an involuntary movement disorder that typically arises from the long-term use of antipsychotic medication in schizoaffective disorders. Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, trunk, or extremities, including lip smacking, grimacing, tongue protrusion, facial movements or blinking, puckering and pursing of the lips. TDs are most common in patients with schizophrenia, schizoaffective disorder, or bipolar disorder who have been treated with antipsychotic medication for long periods, but they occasionally occur in other patients as well.

The key factors driving the growth of the Tardive dyskinesia market are rising schizophrenia patients, increasing bipolar patients, growing antipsychotic prescription, increased use of long-term neuroleptic drugs and increasing incidence of neurological disorders. However, the expansion of the market is hindered by side effects of drugs and under-diagnosed.

The report "Tardive Dyskinesia Market" provides a comprehensive study of the US and Japan tardive dyskinesia market with detailed analysis of market size, growth and penetration of the industry. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The industry comprises few large players such as Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceuticals Industries Ltd. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

Table of Contents

1. Tardive Dyskinesias - An Overview

  • 1.1 Antipsychotics Overview
  • 1.2 Tardive Dyskinesias
  • 1.3 Signs and Symptoms
  • 1.4 Causes
  • 1.5 Treatment
  • 1.6 Existing and Pipeline Drugs

2. The US Tardive Dyskinesia Market Analysis

  • 2.1 The US Tardive Dyskinesia Market by Number of Patients
  • 2.2 The US Tardive Dyskinesia - Number of Patients by Severity
  • 2.3 The US Tardive Dyskinesia Sales by Value
  • 2.4 The US Tardive Dyskinesia Annual Price

3. Japan Tardive Dyskinesia Market Analysis

  • 3.1 Japan Tardive Dyskinesia Market by Number of Patients
  • 3.2 Japan Tardive Dyskinesia - Number of Patients by Severity
  • 3.3 Japan Tardive Dyskinesia Sales by Value
  • 3.4 Japan Tardive Dyskinesia Annual Price

4. The US Tardive Dyskinesia Drugs Market Analysis

  • 4.1 The US Valbenazine Market by Penetration
  • 4.2 The US SD-809 Market by Penetration
  • 4.3 The US Tetrabenazine Market For Tardive Dyskinesia by Penetration

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Rising Schizophrenia Patients
    • 5.1.2 Increasing Bipolar Patients
    • 5.1.3 Growing Antipsychotic Prescription
    • 5.1.4 Increased Use of Long-Term Neuroleptic Drugs
    • 5.1.5 Increasing Incidence of Neurological Disorders
  • 5.2 Market Trends
    • 5.2.1 Medications Causing Tardive Dyskinesia
  • 5.3 Challenges
    • 5.3.1 Side Effects of Drugs
    • 5.3.2 Under-Diagnosed

6. Competitive Landscape

  • 6.1 Comparison between Valbenazine vs. SD-809

7. Company Profiles

  • 7.1 Valeant Pharmaceuticals
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Neurocrine Biosciences
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Teva Pharmaceuticals Industries Ltd.
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies

List of Charts

  • Side Effects of Antipsychotics
  • Signs and Symptoms of Tardive Dyskinesias
  • The US Tardive Dyskinesia Market by Number of Patients (2016-2025)
  • The US Tardive Dyskinesia - Number of Patients by Severity (2016-2025)
  • The US Tardive Dyskinesia Sales by Value (2017-2025)
  • The US Tardive Dyskinesia Annual Price (2016-2025)
  • Japan Tardive Dyskinesia Market by Number of Patients (2016-2025)
  • Japan Tardive Dyskinesia - Number of Patients by Severity (2016-2025)
  • Japan Tardive Dyskinesia Sales by Value (2017-2025)
  • Japan Tardive Dyskinesia Annual Price (2017-2025)
  • The US Valbenazine Market by Penetration (2017-2025)
  • The US SD-809 Market by Penetration (2019-2025)
  • The US Tetrabenazine Market for Tardive Dyskinesia by Penetration (2017-2025)
  • Schizophrenia Patients in the US (2017-2025)
  • Bipolar Patients in the US (2017-2025)
  • Medications Causing Tardive Dyskinesia
  • Comparison between Valbenazine vs. SD-809
  • Valeant Pharmaceuticals Revenue by Segment (2016)
  • Valeant Pharmaceuticals Revenue and Net Income (2012-2016)
  • Neurocrine Biosciences Product Candidates in Clinical Development
  • Neurocrine Biosciences Revenue (2012-2016)
  • Teva Pharmaceuticals Revenue by Segment (2016)
  • Teva Pharmaceuticals Revenue by Region (2016)
  • Teva Pharmaceuticals Revenue and Net Income (2012-2016)
Back to Top